Ardelyx ARDX 深 滬
已收盤 08-07 16:00:00 美东时间
4.00
-0.870
-17.86%
華盛通- 最 高4.27
- 今 開4.05
- 成交量 2007.04万股
- 最 低 3.90
- 昨 收 4.87
- 總市值 9.88亿
- 52周最高 8.40
- 市盈率 靜 --
- 換手率 8.12%
- 52周最低 3.90
- 委 比 56.15%
- 總股本 2.47亿
- 歷史最高 35.48
- 量 比 5.24
- 振 幅 7.60%
- 歷史最低 0.49
- 每 手 1
- 風險率 0.71%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多BTIG Maintains Buy on Ardelyx, Lowers Price Target to $14
BTIG analyst Julian Harrison maintains Ardelyx (NASDAQ:ARDX) with a Buy and lowers the price target from $17 to $14.
08-07 21:45
财报速睇 | Ardelyx 2026财年Q2营收1.21亿美元，同比增长23.8%；归母净利润亏损0.17亿美元，同比亏损缩窄12.4%
华盛资讯8月7日讯，Ardelyx公布2026财年Q2业绩，公司Q2营收1.21亿美元，同比增长23.8%，归母净利润亏损0.17亿美元，同比亏损缩窄12.4%。
08-07 10:51
财报速睇 | Ardelyx 2026财年Q2营收1.21亿美元，同比增长23.5%；归母净利润亏损0.17亿美元，同比亏损缩窄10.5%
华盛资讯8月7日讯，Ardelyx公布2026财年Q2业绩，公司Q2营收1.21亿美元，同比增长23.5%，归母净利润亏损0.17亿美元，同比亏损缩窄10.5%。
08-07 07:07
Ardelyx shares are trading lower after the company reported worse-than-expected Q2 financial results.
Ardelyx shares are trading lower after the company reported worse-than-expected Q2 financial results.
08-07 04:49
Monopar Advances Launch Readiness with Addition of Veteran Commercial Executive Nicole Sweeny to Board of Directors and Expansion of Commercial Leadership Team
Monopar Therapeutics Inc. has appointed seasoned commercial leaders to support the anticipated launch of its first product, ALXN1840, for Wilson disease, pending FDA approval. Nicole Sweeny, former Chief Commercial Officer of KalVista Pharmaceuticals, has joined the Board of Directors. Sharon Funk and Daniel Olmstead have been appointed as Senior Vice Presidents for Sales and Marketing, and Market Access, Distribution, and Patient Services, respe...
07-20 12:00
美股大行评级 | 潜在涨幅117.92%！摩根大通上调Camp4 Therapeutics目标价至9美元，维持"超配"评级
今日重点评级关注：摩根大通：上调Camp4 Therapeutics评级至"超配"，目标价从5美元升至9美元；Canaccord Genuity：维持Rhythm制药"买入"评级，目标价从143美元升至151美元
06-17 11:32
Ladenburg Thalmann Assumes Ardelyx at Buy, Announces Price Target of $16
Ladenburg Thalmann analyst Caroline Palomeque assumes Ardelyx (NASDAQ:ARDX) with a Buy rating and announces Price Target of $16.
06-17 00:53
Ardelyx shares are trading higher after the company reported better-than-expected Q1 sales results.
Ardelyx shares are trading higher after the company reported better-than-expect...
05-02 00:03
电话会总结 ｜ Ardelyx(ARDX)2026财年Q1业绩电话会核心要点
<span style="color:#999999;">编者按：聚焦公司高管观点与展望，深挖业绩背后的信息，助力投资者把握先机。</span><blockquote><p><span style="color:#fa1432;"><strong>业绩回顾</strong></span></p></blockquote><p>• 根据Ardelyx业绩会实录，以下是2026年第一季度财务业绩回顾摘要： ## 1. 财务业绩 **营收表现：** - 总产品收入9,340万美元，同比增长38%（2025年同期为6,780万美元） - Ibsrela收入7,010万美元，同比增长58% - Exposa收入2,330万美元，按报告基准与去年同期基本持平 **盈利能力：** - 净亏损3,760万美元，折合每股亏损0.15美元 - 毛净调整率（Gross-to-Net）为36.4% **现金状况：** - 季度末现金、现金等价物及短期投资总额为2.381亿美元 ## 2. 财务指标变
05-01 12:16
期权扫描 | 英伟达期权成交总量达410.83万张，较前一日增加99.65万张
SPX的看跌期权成交量262.87万张，看涨期权成交量254.33万张，看跌/看涨交易量比率约1.03。
05-01 11:34
